이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance (PERSEUS)

2026년 10월 9일 업데이트: Simone Vanni, Azienda Ospedaliero-Universitaria Careggi

The PERSEUS Registry - Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance

PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.

연구 개요

상세 설명

BACKGROUND AND SCIENTIFIC RATIONALE

Pulmonary embolism (PE) represents a major cause of emergency department (ED) presentation, critical care admission, and early mortality. Despite advances in diagnostic algorithms and therapeutic strategies, intermediate- and high-risk PE patients remain challenging to risk-stratify dynamically during the acute phase. Current prognostic tools often rely solely on baseline single-point parameters, neglecting acute pathophysiological changes during the initial 48 hours of treatment. The PERSEUS Registry is designed to bridge this gap by capturing comprehensive, granular real-world data spanning the acute presentation, dynamic in-hospital course, and long-term surveillance.

STUDY DESIGN AND COHORTS

Time perspective: ambispective (retrospective and prospective cohorts, described below).

PERSEUS is an observational, ambispective, multicenter registry comprising two distinct phases:

  1. Retrospective Phase (Historical Cohort): Includes consecutive adult patients diagnosed with acute PE from January 1, 2023, up to the date of local Ethics Committee approval at each participating site. Data are abstracted from medical records.
  2. Prospective Phase (Contemporary Cohort): Enrolls consecutive adult patients presenting with acute PE after local Ethics Committee approval, extending for a continuous enrollment period of 5 years. Data are collected during routine care.

STUDY SETTING AND CLINICAL CONTINUUM OF CARE

Data collection spans the entire continuum of clinical care across participating academic, tertiary, and regional hospitals:

  • Baseline Presentation (T0): Captures pre-hospital emergency medical service (EMS) data (initial vital signs, cardiac arrest, point-of-care ultrasound [POCUS], pre-hospital anticoagulation or thrombolysis), ED arrival parameters, clinical symptoms, arterial blood gas analysis, admission laboratory biomarkers (high-sensitivity troponin, BNP/NT-proBNP, lactate, D-dimer, renal function), electrocardiographic patterns, and multiorgan diagnostic imaging (CT pulmonary angiography [CTPA], complete echocardiography/POCUS, and compression venous ultrasound [CUS]).
  • Dynamic In-Hospital Reassessment (T1-T4): To capture real-world hemodynamic and respiratory trajectories, serial parameters documented during standard clinical monitoring are recorded across predefined temporal windows: T1 (3-6 hours), T2 (6-12 hours), T3 (12-24 hours), and T4 (24-48 hours). Parameters include serial vital signs, shock index, respiratory support modalities, serial lactate/troponin kinetics, echocardiographic right ventricular function changes, and need for escalating hemodynamic or respiratory support (vasopressors, inotropes, non-invasive ventilation, mechanical ventilation, or ECMO).
  • Hospital Discharge & Complications: Documents in-hospital adverse events, need for rescue reperfusion, procedural complications, bleeding events, length of stay, and vital status at discharge.
  • Follow-up Surveillance: Thirty-day status is ascertained from clinical records. Follow-up then reflects routine care at 3 and 12 months and annually thereafter up to 5 years (in-person visit, telemedicine, telephone contact or review of clinical documentation), with regional mortality registries used to ascertain vital status when needed. Follow-up collects all-cause survival, cause of death, VTE recurrence, major and clinically relevant non-major bleeding, persistent functional limitation (modified Rankin Scale, exertional dyspnea, six-minute walk test when performed) and the development of chronic thromboembolic pulmonary hypertension (CTEPH).

OUTCOMES

Outcome definitions and time frames are reported in the Outcome Measures section.

DATA MANAGEMENT, QUALITY ASSURANCE, AND ETHICAL GOVERNANCE

Data collection is centralized using an electronic Case Report Form (eCRF) deployed on the REDCap (Research Electronic Data Capture) platform hosted on secure institutional servers at Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).

  • Privacy and Data Segregation: Strict GDPR compliance is maintained. Patient data are pseudonymized at source by the local site investigator using site-specific Subject IDs. The decoding key linking the alphanumeric ID to personal identifiers is maintained exclusively at the local participating hospital under the responsibility of the local Principal Investigator.
  • Data Access Groups (DAGs): REDCap DAGs are enforced to compartmentalize site-level access, ensuring participating centers can exclusively view, enter, and edit their own center's records, with no unauthorized cross-center data visibility.
  • Quality Assurance: The eCRF includes built-in validation rules (range and logic checks). The coordinating center performs regular central monitoring for inconsistencies, outliers and missing data, and discrepancies are resolved with each center through a formal query process. The Steering Committee reviews enrollment, data quality and protocol adherence every 6 months.
  • Regulatory Framework: Protocol version 2.0 (7 May 2026) received a favourable opinion from the Comitato Etico Regione Toscana - Area Vasta Centro (CEAVC, register no. 30742_oss, meeting of 9 June 2026) for the sites of Azienda Ospedaliero-Universitaria Careggi and Azienda USL Toscana Centro. Participation of other national and international centers is subject to approval of a protocol amendment and of the competent local ethics committees. The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice principles and applicable privacy regulations (including Article 110-bis of the Italian Privacy Code).

연구 유형

관찰

등록 (추정된)

5000

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Madrid, 스페인
        • 모병
        • Hospital Universitario Ramón y Cajal
        • 연락하다:
        • 수석 연구원:
          • David Jiménez, MD, PhD
      • Lido di Camaiore, 이탈리아
        • 모병
        • Ospedale Versilia - Azienda USL Toscana Nord Ovest
        • 연락하다:
        • 수석 연구원:
          • Giuseppe Pepe, MD
      • Naples, 이탈리아, 80131
        • 모병
        • AORN Antonio Cardarelli
        • 연락하다:
        • 수석 연구원:
          • Angela Iannuzzi, MD
      • Perugia, 이탈리아, 06129
        • 모병
        • Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
        • 연락하다:
        • 수석 연구원:
          • Cecilia Becattini, MD, PhD
      • Pisa, 이탈리아
        • 모병
        • Azienda Ospedaliero-Universitaria Pisana - Ospedale Cisanello
        • 연락하다:
        • 수석 연구원:
          • Lorenzo Ghiadoni, MD, PhD
      • Torino, 이탈리아, 10126
        • 모병
        • AOU Città della Salute e della Scienza di Torino - Presidio Molinette
        • 연락하다:
        • 수석 연구원:
          • Fulvio Morello, MD
    • Tuscany
      • Bagno a Ripoli, Tuscany, 이탈리아, 50012
      • Borgo San Lorenzo, Tuscany, 이탈리아, 50032
      • Empoli, Tuscany, 이탈리아, 50053
      • Florence, Tuscany, 이탈리아, 50134
        • 모병
        • Azienda Ospedaliero-Universitaria Careggi
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Simone Vanni, MD, PhD
        • 부수사관:
          • Matteo Gabriele Monda, MD
      • Florence, Tuscany, 이탈리아, 50122
      • Florence, Tuscany, 이탈리아, 50143
      • Pescia, Tuscany, 이탈리아, 51017
      • Pistoia, Tuscany, 이탈리아, 51100
      • Prato, Tuscany, 이탈리아, 59100
      • Warsaw, 폴란드
        • 모병
        • Medical University of Warsaw - Infant Jesus Teaching Hospital
        • 연락하다:
        • 수석 연구원:
          • Piotr Pruszczyk, MD, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Consecutive adults with objectively confirmed acute pulmonary embolism diagnosed at participating hospitals, from emergency department presentation through hospitalization, including patients presenting with obstructive shock or cardiac arrest.

설명

Inclusion Criteria:

  • Age 18 years or older at the time of presentation.
  • Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods:
  • Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree;
  • Ventilation/perfusion (V/Q) lung scintigraphy demonstrating high-probability mismatch;
  • Conventional catheter-directed pulmonary angiography;
  • In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi.
  • For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion.
  • Written informed consent obtained from the patient or legal surrogate, or waiver/exception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients.

Exclusion Criteria:

  • Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: OTHER

코호트 및 개입

그룹/코호트
개입 / 치료
Adults with acute pulmonary embolism

Consecutive adults with objectively confirmed acute pulmonary embolism, in two cohorts: a retrospective cohort (diagnoses from 1 January 2023 until local ethics committee approval; data abstracted from medical records) and a prospective cohort (consecutive enrollment after approval, for 5 years; data collected during routine care).

Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.

다른 이름들:
  • Routine Clinical Practice, Usual Care

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
All-cause mortality at 30 days
기간: 30 days after diagnosis

Proportion of patients who die from any cause within 30 days of the objectively confirmed diagnosis of acute pulmonary embolism. Vital status is ascertained from hospital records, review of clinical documentation and, when needed, regional mortality registries.

30 days after diagnosis
PE-related mortality at 30 days
기간: 30 days after diagnosis

Proportion of patients whose death within 30 days is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism (PE). Fatal PE is defined as death occurring after objectively confirmed PE (index or recurrent event) in the absence of other identifiable causes, or confirmed at autopsy. For deaths occurring at home, information on the cause of death is actively sought.

30 days after diagnosis

2차 결과 측정

결과 측정
측정값 설명
기간
Hemodynamic decompensation
기간: From diagnosis to hospital discharge or day 30, whichever comes first

Proportion of patients with new occurrence, after the initial assessment, of at least one of: persistent hypotension (systolic blood pressure <90 mmHg for 15 minutes or longer) or shock; need for continuous vasopressor or inotrope infusion; invasive mechanical ventilation; cardiac arrest; rescue reperfusion therapy (systemic, catheter-directed or surgical) for clinical deterioration. Reperfusion given as the initial treatment strategy is not counted as an event.

From diagnosis to hospital discharge or day 30, whichever comes first
All-cause mortality during follow-up
기간: 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients who die from any cause during follow-up.

3 months, 12 months, and annually up to 5 years after diagnosis
PE-related mortality during follow-up
기간: 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients whose death during follow-up is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism, as defined for the 30-day PE-related mortality outcome.

3 months, 12 months, and annually up to 5 years after diagnosis
Recurrent venous thromboembolism
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with any new episode of pulmonary embolism or deep vein thrombosis (lower or upper limb, proximal or distal) confirmed by objective testing. Superficial vein thrombosis is not counted.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Major bleeding (ISTH criteria)
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH): overt bleeding that is fatal; or occurs in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome); or causes a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or leads to transfusion of two or more units of whole blood or red cells. Major bleeding is additionally classified as life-threatening if it is extracranial bleeding causing shock or intracranial hemorrhage with a Glasgow Coma Scale score below 14.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Clinically relevant non-major bleeding
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with bleeding not meeting the criteria for major bleeding but requiring medical intervention, unscheduled contact with a physician, or temporary cessation of antithrombotic therapy.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Chronic thromboembolic pulmonary hypertension (CTEPH)
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with CTEPH diagnosed during routine follow-up: mean pulmonary arterial pressure >20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance >2 Wood units at right heart catheterization, with mismatched perfusion defects after at least 3 months of therapeutic anticoagulation (2022 ESC/ERS criteria). Diagnostic tests are performed only when clinically indicated.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Persistent functional limitation after pulmonary embolism (post-PE syndrome)
기간: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Persistent or worsened exertional dyspnea compared with pre-event status, modified Rankin Scale score, and six-minute walk distance when performed in routine care.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Simone Vanni, MD, PhD, Azienda Ospedaliero-Universitaria Careggi / University of Florence
  • 연구 책임자: Matteo Gabriele Monda, MD, Azienda Ospedaliero-Universitaria Careggi / University of Florence

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 6월 19일

기본 완료 (추정된)

2031년 7월 1일

연구 완료 (추정된)

2032년 7월 1일

연구 등록 날짜

최초 제출

2026년 9월 28일

QC 기준을 충족하는 최초 제출

2026년 9월 28일

처음 게시됨 (실제)

2026년 10월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 15일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 9일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Pseudonymized individual participant data underlying published results may be shared with qualified researchers for methodologically sound proposals that fall within the scientific scope of the registry and do not overlap with analyses planned by the PERSEUS investigators. Sharing requires approval by the PERSEUS Steering Committee, approval by the competent ethics committee and a data transfer agreement with Azienda Ospedaliero-Universitaria Careggi, in compliance with the GDPR and the Italian Privacy Code.

IPD 공유 기간

Data will become available beginning 12 months after formal publication of the primary registry outcomes manuscript and will remain accessible for a period of 5 years.

IPD 공유 액세스 기준

Access requests must be submitted in writing to the Principal Investigator (simone.vanni@unifi.it) and the PERSEUS Steering Committee, including a detailed scientific protocol and statistical analysis plan. Proposals will be evaluated for scientific merit, feasibility, ethical compliance, and non-redundancy by the Steering Committee. Prior to data release, requestors and their home institutions must sign a formal Data Transfer Agreement (DTA) with Azienda Ospedaliero-Universitaria Careggi and obtain appropriate local ethical approval.

IPD 공유 지원 정보 유형

  • 연구_프로토콜

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다